Stefano Tamberi

TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.

TL;DR: Carboplatin/PLD was not superior to carboplarin/paclitaxel, which remains the standard first-line chemotherapy for advanced ovarian cancer, however, given the observed CIs and the different toxicity, carboplatin-PLD could be considered an alternative to standard therapy.

TL;DR: The findings suggest that a phase 3 study of the combination of weekly paclitaxel plus pazopanib for patients with platinum-resistant or platinum-refractory advanced ovarian cancer is warranted.

TL;DR: Results indicate that II, in particular NLR, are good prognostic and predictive markers for mCRC patients who are candidates for CT plus Bev.

TL;DR: It is confirmed that nivolumab is active in non-squamous NSCLC patients with brain metastases, despite their poor prognosis, and its safety profile is concordant with results in the EAP overall population and in patients with other malignancies.